moxifloxacin has been researched along with mobic in 7 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (mobic) | Trials (mobic) | Recent Studies (post-2010) (mobic) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 1,739 | 396 | 936 |
| Protein | Taxonomy | moxifloxacin (IC50) | mobic (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 1.5593 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.4364 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.1514 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hasunuma, T; Jang, IJ; Kaneko, M; Kaniwa, N; Kawai, S; Saito, Y; Takeuchi, M; Tohkin, M; Uyama, Y; Watanabe, H; Yamazoe, Y; Yimin, C | 1 |
1 review(s) available for moxifloxacin and mobic
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for moxifloxacin and mobic
| Article | Year |
|---|---|
Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians.
Topics: Adult; Asian People; Cytochrome P-450 CYP2C9; Fluoroquinolones; Glucuronosyltransferase; Humans; Liver-Specific Organic Anion Transporter 1; Male; Meloxicam; Moxifloxacin; Polymorphism, Genetic; Simvastatin; Thiazines; Thiazoles; White People; Young Adult | 2016 |
5 other study(ies) available for moxifloxacin and mobic
| Article | Year |
|---|---|
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |